Received Apr 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | — | — |
| MNP | MENINGOCOCCAL CONJUGATE (PENBRAYA) | PFIZER\WYETH | UNK | — | — |
The 3 dose Bexsero vaccine series was administered to a patient followed by a 1-year Booster dose of Penbraya.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included MENINGOCOCCAL VACCINE A/B/C/W/Y (PENBRAYA) for prophylaxis. Previously administered products included Bexsero (received first dose on unknown date) and Bexsero (received second dose on unknown date). On an unknown date, the patient received the 3rd dose of Bexsero and PENBRAYA. On an unknown date, an unknown time after receiving Bexsero and an unknown time after receiving PENBRAYA, the patient experienced interchange of vaccine products (Verbatim: The 3 dose Bexsero vaccine series was administered to a patient followed by a 1-year Booster dose of Penbraya.). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-APR-2026 The reporter called on behalf of a patient that received three doses of Bexsero and then received Penbraya as a 1-year booster dose. The batch number was not provided, and we are unable to contact the reporter.